highlight today earn
sold report unev quarter anticip hbr
miss hold combin compani guid weigh sentiment
catalyst share march guidanc call acceler
pharma segment ebit chang split high level discuss driver set
posit tone rais price target much anticip guidanc
rang top-line growth long-term growth quantifi key
understand underli build block provid march
analyst day highlight today print
benefit ratio hbr miss consensu intern estim bp
driven one-tim reconcili item miss on-going flu
season remain hbr bp consensu
bp impli high end manag guidanc rang result
headwind quarter flu headwind line impact discuss
last week earn call compani greater earn
exposur medicaid member particularli children affect
type flu strain common strain flu season
expect molina report monday close report similar trend
headwind primari attribut factor reconcili
outstand claim settl sever state result centen
favor reimburs go forward off-set immateri
cnc/wcg combin compani guidanc come next month
built expect head print updat
guidanc follow januari close wellcar group transact
manag reiter earn floor qualifi least break even
accret first full year provid detail guidanc
march headwind factor guidanc includ delay north
carolina medicaid contract start date earn contribut wellcar
first day januari transact close jan instead jan
billion divestitur requir close deal
estim combin account headwind tailwind includ wellcar
pdp busi growth million member swing factor guidanc includ
pbm opportun evalu manag benchmark
new wellcare/ contract rxadvanc econom well potenti share
repurchas acceler debt pay integr effort alreadi take
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
place includ align combin entiti medicar busi bid
wellcar brand name
medicaid margin pace improv follow rate increas
composit medicaid rate increas reflect state renegoti
off-set margin pressur reverif rfp front
award tx star chip expect announc sometim
februari delay januari wherea louisiana continu
oper emerg contract await decis appeal follow loss
contract award announc last year
upsid attribut combin continu strength us
pharma segment below-the-lin item earli januari rais
ep guidanc today call
manag provid addit color sourc upsid emphas
improv confid upper-end us pharma segment ebit guidanc
net-net estim continu strength us pharma segment contribut
one-third upsid follow reduc corpor
expens impact time invest continu
strength medsurg contribut share repurchas
us pharma segment ebit guidanc increas high-end
y/i growth medsurg ebit guidanc updat low-doubl digit y/i
growth us pharma impli ebit million repres y/i
declin deceler growth prior quarter
us pharma ebit grew respect mix shift associ
onboard increment volum larger low-margin client highlight
main driver anticip quarterli variat notabl manag
state gener buy sell-sid trend continu stabl
exit mechan unveil conjunct
morn earn announc split-off
time exit still expect sometim april octob
commentari call suggest exit materi impact
earn cash balanc model place exit fiscal
estim headwind ep
preliminari commentari suggest tailwind
envis tailwind includ continu improv core underli
fundament benefit cost save buyback wherea va contract
renew expect materi headwind earn uk
reimburs retail trend highlight key uncertainti
updat estim increas price target
updat forecast reflect updat guidanc model
ep within guidanc rang
updat dcf-base price target impli
ebitda exclud opioid liabil multipl slightli
averag multipl mck share
revenu guidanc key area focu manag
guid revenu growth midpoint versu
consensu adjust acquisit exit adventist health
contract organ growth expect mid point notabl guidanc
includ unannounc addit divestitur product
servic align new strateg focu
initi lt revenu guidanc modestli outlook
discuss last year compani higher level select outsourc
contract highlight key differ new prior guidanc
feder contract va expect continu add million
top-line growth estim strateg
growth initi includ healtheint long-
term post-acut contribut million revenu y/i
highlight meaning contributor go forward detail
come analyst day himss march
capit alloc manag continu focus
opportun strateg asset add compani portfolio addit
still million share buy-back capac remain
exist billion buy-back program schedul complet end
contribut estim full year ep guid
strength us pharma
strength medsurg
note item may sum due round
earn
earn
growth specialti revenu strong balanc sheet mitig opioid risk
growth rate mid-term ebit margin wacc addit assum
global opioid litig settlement estim respons
largest distributor
pharmaceut medic suppli
estim specialti
revenu billion second largest
exposur among three distributor
segment includ faster-grow higher-
although largest
potenti liabil attribut opioid-
relat litig among distributor
believ also
strongest balanc sheet best
abil weather potenti liabil
continu risk brand drug
futur litig
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
feb gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
view descript risk reward theme
impli ev/ebitda bull case
assum brand inat goe hsd
gener inat lsd global opioid
liabil lower sell-sid discount
custom higher top-line growth
gross margin specialti
impli multipl in-lin averag
forward ev/ebitda multipl past
impli ev/ebitda base case
assum brand inat remain lsd-
msd gener deation lsd global
opioid liabil
impli multipl modestli averag
forward ev/ebitda multipl past
impli ev/ebitda bear case
assum brand inat goe zero
opioid liabil higher sell side
discount custom lower top-line
growth gross margin specialti
impli multipl in-lin minimum
forward ev/ebitda multipl past
drug price increas particularli januari
gener manufactur commentari gener
news ow opioid litig settlement
view explan region hierarchi
research highest favor quintil
increas brand inat
acceler growth specialti drug
distribut servic
reimburs headwind europ abat
signic slowdown brand inat
deterior gener price deation
continu price pressur margin eros
increas opioid legal settlement payment
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
lt growth depend new strateg initi partnership
dcf-deriv pt wacc medium-term growth rate termin growth
market leader global
ehr market account share
us market market alreadi
penetr greeneld opportun
hospit continu shift
spend area outsid core
popul key manag
deliv long-term top-line growth
strateg growth initi
consum employ medicaid
provid upsid option requir
increment invest outsid
cut initi expand
oper margin near-to-mid term
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
feb gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
price-to-earnings multipl appli bull
price-to-earnings multipl appli bull
case ep estim
case ep estim revenu
re-acceler high singl digit due
faster-than-expect uptak revenu
offer newer offer ebitda
margin expand beyond rang
price-to-earnings multipl appli base
price-to-earnings multipl appli base
case ep estim
case ep estim revenu
grow mid-high single-digit
ebitda margin rang
price-to-earnings multipl appli bear
price-to-earnings multipl appli bear
case ep estim
case ep estim revenu
growth deceler low-single-digit
ebitda margin rang
analyst day himss
view explan region hierarchi
research highest favor quintil
faster expect ramp va contract
revenu acceler non-cor product
popul health itwork
expans hospit hcit budget
revenu deceler ebit declin
ration low-margin contract
lack traction non-cor product
implement delay va contract
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
multipl growth lever wcg rxadvanc execut success
calcul price target appli price-to-earnings multipl base case ep
normal hif multipl reect turn discount multipl
trade discount medicar sell
adjust repeal hif estimate turn
largest medicaid player
market share
wellcar acquisit expand
market presenc medicar advantag
fastest grow market
stand-alone wellcar outperform
suggest potenti upsid deal accret
base estim break-even
mid-single-digit accret
addit upsid opportun
insourc pbm integr
medic pharmaci benet
repeal would headwind
assign low probabl outcom
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
feb gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
ep plu hif
discount multipl
discount multipl
in-lin averag discount
last year medicar
advantag take exchang stabil
see multipl growth driver
potenti headwind ceas materi
due dc gridlock medicar ramp
gap medicaid group
ep plu hif
multipl
multipl trade
discount medicar
sell adjust
repeal hif estimate turn base case
core execut medicar advantag
expans top exchang protabl
ep plu hif
multipl
multipl discount in-
line stock trade
trough last price cycl
medicar advantag fail launch
becom headwind medicar
advantag stall loss core
medicaid busi fide fail reach
texa unit state constitution
view explan region hierarchi
research highest favor quintil
deal wcg drive acceler growth
margin perform high end
rxadvanc grow big market pharmaci
wcg out-performance drive upsid
loss core medicaid contract
exchang protabl less expect
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
servic
gener administr expens
amort intang
invest incom incom
incom continu oper
 revenu
tax rate hif
net incom continu oper
